Team – Topadur Pharma

Topadur Pharma AG is a clinical-stage company developing novel therapies to restore healthy blood flow and stimulate tissue regeneration. We focus on challenging-to-treat age-related diseases characterized by microvascular dysfunction and impaired healing. With a precision-targeted approach, we aim for localized healing with minimal systemic exposure.

Founded to solve the microcirculation challenge

Founded in Switzerland in 2015, Topadur brings together pharma leaders and seasoned scientists driven by a shared belief: that impaired microcirculation is a critical but often overlooked key driver of disease progression. Recognizing a critical unmet need in treatment, Topadur developed a novel approach focused on cGMP regulation – a key mechanism for vascular repair and tissue regeneration.

DualTOP^®: Precision repair through dual mechanism of action

Topadur Pharma’s proprietary DualTOP^® platform leverages a unique dual mechanism with unprecedented efficacy, inducing vasodilation and stimulating new blood vessel formation to restore oxygen and nutrient supply to tissues. By delivering treatment directly to the affected tissue, DualTOP^® is designed to maximize therapeutic benefit while minimizing systemic exposure and reducing side effects.

Find out more about our science

First-in-class pipeline based on validated science

Backed by preclinical and early clinical validation, our pipeline is anchored by three first-in-class programs addressing significant unmet needs: TOP-N53 for digital ulcers in systemic sclerosis as well as diabetic foot ulcers, and TOP-M119 for androgenetic alopecia.

Our capital-efficient, partnership-driven strategy aims to rapidly advance our assets through Phase 2 clinical trials. Beyond these lead indications, our DualTOP^® platform shows promising potential in additional indications where restoring microcirculation could be transformative, fueling a focused, yet expandable innovation pipeline.

Learn more about our portfolio

Working with purpose for better outcomes

Behind every breakthrough at Topadur is our multidisciplinary team, powered by decades of experience across biotech, medicine, and business.

Building a global future together

Topadur has built a strong network of international collaborations with globally recognized partners, helping us accelerate the development of therapies for the patients who need them most.

Switzerland

Prof. Oliver Distler | University of Zurich
Lung Fibrosis

Prof. Nicole Lindenblatt | University Hospital Zurich
Wound healing

Prof. Sabine Werner | ETH Zürich
Wound healing

Prof. Matthias Turina | University Hospital Zurich
Oncology

Prof. Martin Pruschy | University of Zurich
Oncology

Prof. Roger Schibli | Paul Scherrer Institute
Radio Oncology

Prof. Michael Scharl | University Hospital Zurich
Inflammatory Bowel Disease, Oncology

Prof. Georgios Imanidis | FHNW University of Applied Sciences
Formulations development

Prof. Jörn Dengjel | University of Fribourg
Proteomics

Prof. Botond Roska | Institute of Molecular and Clinical Ophthalmology Basel
Ophthalmology

Prof. Christian Grimm | University of Zurich
Ophthalmology

France

Prof. Jean-Luc Cracowski | Hospital Center University Grenoble Alps
Wound healing

Prof. Sophie Blaise | Hospital Center University Grenoble Alps
Systemic Sclerosis

Prof. Yannick Allanore | Cochin Hospital Paris
Systemic Sclerosis

Prof. Marie-Elise Truchetet | Hospital Center University Bordeaux
Systemic Sclerosis

Prof. Davide Launay | Hospital Center University Lille
Systemic Sclerosis

Germany

Prof. Ralf Ludwig | University of Lübeck
Skin fibrosis

Spain

Prof. Javier Milara | University of Valencia
Skin and lung fibrosis

Prof. Julio Cortijo | University of Valencia
Skin fibrosis

South Korea

Prof. Hyungil Jung | Yonsei University & Seoul National University
Formulation

Prof. Ohsang Kwon | Yonsei University & Seoul National University
Formulation

Clinical stage company driving progress in healthy aging